[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AU2002349676A1 - 4-oxoquinoline derivatives - Google Patents

4-oxoquinoline derivatives

Info

Publication number
AU2002349676A1
AU2002349676A1 AU2002349676A AU2002349676A AU2002349676A1 AU 2002349676 A1 AU2002349676 A1 AU 2002349676A1 AU 2002349676 A AU2002349676 A AU 2002349676A AU 2002349676 A AU2002349676 A AU 2002349676A AU 2002349676 A1 AU2002349676 A1 AU 2002349676A1
Authority
AU
Australia
Prior art keywords
oxoquinoline derivatives
oxoquinoline
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002349676A
Inventor
Tohru Hasegawa
Takuya Ikeda
Keita Kono
Hitoshi Kurata
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sankyo Co Ltd
Original Assignee
Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co Ltd filed Critical Sankyo Co Ltd
Publication of AU2002349676A1 publication Critical patent/AU2002349676A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2002349676A 2001-11-19 2002-11-19 4-oxoquinoline derivatives Abandoned AU2002349676A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2001-353064 2001-11-19
JP2001353064 2001-11-19
PCT/JP2002/012077 WO2003043992A1 (en) 2001-11-19 2002-11-19 4-oxoquinoline derivatives

Publications (1)

Publication Number Publication Date
AU2002349676A1 true AU2002349676A1 (en) 2003-06-10

Family

ID=19165142

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002349676A Abandoned AU2002349676A1 (en) 2001-11-19 2002-11-19 4-oxoquinoline derivatives

Country Status (3)

Country Link
AU (1) AU2002349676A1 (en)
TW (1) TW200300349A (en)
WO (1) WO2003043992A1 (en)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
DE60329318D1 (en) 2002-11-20 2009-10-29 Japan Tobacco Inc 4-OXOCHINOLINE COMPOUNDS AND THEIR USE AS HIV INTEGRASE INHIBITORS
CN101006076B (en) 2004-06-24 2010-09-29 沃泰克斯药物股份有限公司 Modulators of ATP-binding cassette transporters
DK3219705T3 (en) 2005-12-28 2020-04-14 Vertex Pharma PHARMACEUTICAL COMPOSITIONS OF THE AMORPHIC FORM OF N- [2,4-BIS (1,1-DIMETHYLETHYL) -5-HYDROXYPHENYL] -1,4-DIHYDRO-4-OXOQUINOLIN-3-CARBOXAMIDE
KR101023635B1 (en) 2006-03-06 2011-03-22 니뽄 다바코 산교 가부시키가이샤 Method for producing 4-oxoquinoline compound
WO2007102499A1 (en) * 2006-03-06 2007-09-13 Japan Tobacco Inc. Process for production of 4-oxoquinoline compound
CN102766098B (en) 2006-09-12 2016-03-30 吉里德科学公司 Prepare method and the intermediate of integrase inhibitor
AR068403A1 (en) 2007-09-11 2009-11-18 Gilead Sciences Inc PROCESS AND INTERMEDIARIES FOR THE PREPARATION OF INTEGRASA INHIBITORS
EP2821400B1 (en) 2009-03-20 2017-09-27 Vertex Pharmaceuticals Incorporated Process for making modulators of cystic fibrosis transmembrane conductance regulator
EP3400944B1 (en) 2010-11-08 2020-07-15 Albireo AB Ibat inhibitors for the treatment of liver diseases
MX2014010253A (en) 2012-02-27 2014-11-12 Vertex Pharma Pharmaceutical composition and administration thereof.
KR20150040340A (en) 2012-08-03 2015-04-14 길리애드 사이언시즈, 인코포레이티드 Process and intermediates for preparing integrase inhibitors
JP6751020B2 (en) 2014-06-25 2020-09-02 Ｅａファーマ株式会社 Solid preparation and method for preventing or reducing coloration thereof
WO2016057730A1 (en) 2014-10-07 2016-04-14 Strohmeier Mark Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
PE20181197A1 (en) 2015-10-14 2018-07-23 Bristol Myers Squibb Co 2,4-DIHYDROXY-NICOTINAMIDES AS AGONISTS OF THE APELIN RECEPTOR (APJ)
US10786529B2 (en) 2016-02-09 2020-09-29 Albireo Ab Oral cholestyramine formulation and use thereof
US10441604B2 (en) 2016-02-09 2019-10-15 Albireo Ab Cholestyramine pellets and methods for preparation thereof
US10441605B2 (en) 2016-02-09 2019-10-15 Albireo Ab Oral cholestyramine formulation and use thereof
AR107973A1 (en) 2016-03-24 2018-07-04 Bristol Myers Squibb Co 6-HYDROXI-4-OXO-1,4-DIHYDROPIRIMIDIN-5-CARBOXAMIDS AS AN APJ AGONIST
CA3071285A1 (en) 2017-08-09 2019-02-14 Albireo Ab Cholestyramine granules, oral cholestyramine formulations and use thereof
CA3100113A1 (en) 2018-06-05 2019-12-12 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
US10793534B2 (en) 2018-06-05 2020-10-06 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
MX2020013774A (en) 2018-06-20 2021-03-02 Albireo Ab Crystal modifications of odevixibat.
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
US10975045B2 (en) 2019-02-06 2021-04-13 Aibireo AB Benzothiazepine compounds and their use as bile acid modulators
US10941127B2 (en) 2019-02-06 2021-03-09 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
CN114761018A (en) 2019-12-04 2022-07-15 阿尔比里奥公司 Benzothiadiazepine compounds and their use as bile acid modulators
JP2023504647A (en) 2019-12-04 2023-02-06 アルビレオ・アクチボラグ Benzothia(di)azepine compounds and their use as bile acid modulators
IL293379A (en) 2019-12-04 2022-07-01 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
US11014898B1 (en) 2020-12-04 2021-05-25 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
CA3158181A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
EP4188541A1 (en) 2020-08-03 2023-06-07 Albireo AB Benzothia(di)azepine compounds and their use as bile acid modulators
CA3196488A1 (en) 2020-11-12 2022-05-19 Albireo Ab Odevixibat for treating progressive familial intrahepatic cholestasis (pfic)
WO2022117778A1 (en) 2020-12-04 2022-06-09 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
US11878958B2 (en) 2022-05-25 2024-01-23 Ikena Oncology, Inc. MEK inhibitors and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10130241A (en) * 1996-10-31 1998-05-19 Wakunaga Pharmaceut Co Ltd New pyridonecarboxylic acid derivative or its salt and medicine comprising the same
AU1302301A (en) * 1999-11-08 2001-06-06 Sankyo Company Limited Nitrogenous heterocycle derivatives

Also Published As

Publication number Publication date
WO2003043992A1 (en) 2003-05-30
TW200300349A (en) 2003-06-01

Similar Documents

Publication Publication Date Title
AU2002349676A1 (en) 4-oxoquinoline derivatives
AU2002313565A1 (en) Putter-heads
AU2002363600A1 (en) Novel phenyl-propargylether derivatives
AU2002358715A1 (en) Tetrahydrobenzfluorene derivatives
AU2002313943A1 (en) Electromobile
AU2002226571A1 (en) Biligands
AU2001100406A4 (en) DriverSMS
AU2002313073A1 (en) Phytocystatin
AU2002255269B8 (en) 2-Iminopyrrolidine derivatives
AU2002225034A1 (en) Rustmicin derivatives
AU2002249205A1 (en) Bis-triazinylaminobenzoxazole derivatives
AU2002325368A1 (en) Benzoylcyclohexenone derivatives
AU2002350425A1 (en) 6-phenyldihydropyrrolopyrimidinedione derivatives
AU2002253080A1 (en) Biurethane derivatives
AU2002230196A1 (en) Dicarba-closo-dodecarborane derivatives
AU2002255269A1 (en) 2-Iminopyrrolidine derivatives
AU2002354530A1 (en) 4-phenylpyran-2-one derivatives
AU2002302578A1 (en) Amido-diphenyl derivatives
AU2002305184A1 (en) Cycloalkenylsulfonamide derivatives
AU2002257925A1 (en) Numberplates
AU2002313234A1 (en) Novel endomorphine derivatives
AU2002328796A1 (en) Novel aminoazetidine, -pyrrolidine and -piperidine derivatives
AU2002343546A1 (en) Beta-carbolin derivatives as ptp-inhibitors
AU2001100214A4 (en) Dolly-trolley
AU2002100746A4 (en) Adrail

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase